Managers / Q4 2018 · view latest →
Essex Woodlands Management, Inc.
CIK 0001542339 · 21 WATERWAY AVE, STE 150, THE WOODLANDS, TX, 77380 · 281-364-1555
Summary
Essex Woodlands Management, Inc. reported $251M in U.S.-listed holdings across 8 positions for Q4 2018.
The portfolio is heavily concentrated: RVNCEUR alone accounts for 36.5% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 64.7% · $163M
- Other · 35.3% · $89M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RVNCEURREVANCE THERAPEUTICS INC | NEW | +3.34M | 3.34M | +$92M | $92M |
| EYEPOINT | NEW | +41.90M | 41.90M | +$79M | $79M |
| AXGNAXOGEN INC | NEW | +2.74M | 2.74M | +$56M | $56M |
| 4875MEDICINOVA INC | NEW | +1.17M | 1.17M | +$15M | $15M |
| ENDOLOGIX INC | NEW | +1.26M | 1.26M | +$5M | $5M |
| CORIUM | NEW | +0 | 0 | +$3M | $3M |
| CATALYST | NEW | +78.6K | 78.6K | +$625,000 | $625,000 |
| ACURACURA PHARMACEUTICALS INC | NEW | +1.96M | 1.96M | +$215,000 | $215,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2018
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RVNCEURREVANCE THERAPEUTICS INChistory → | COM | 36.54% | $92M | 3.34M |
| 2 | EYEPOINT | COM | 31.54% | $79M | 41.90M |
| 3 | AXGNAXOGEN INChistory → | COM | 22.29% | $56M | 2.74M |
| 4 | 4875MEDICINOVA INChistory → | COM | 5.82% | $15M | 1.17M |
| 5 | ENDOLOGIX INC | COM | 2.13% | $5M | 1.26M |
| 6 | CORIUM | COM | 1.34% | $3M | 0 |
| 7 | CATALYST | COM | 0.25% | $625,000 | 78.6K |
| 8 | ACURACURA PHARMACEUTICALS INC | COM | 0.09% | $215,000 | 1.96M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $251M | 5 | May 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $318M | 6 | Feb 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $307M | 6 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $279M | 6 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $347M | 6 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $433M | 7 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $350M | 7 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $307M | 7 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $345M | 7 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $404M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $113M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $173M | 7 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $179M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $242M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $242M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $414M | 9 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $445M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $451M | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $677M | 9 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $640M | 9 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $385M | 8 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $188M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $204M | 8 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $155M | 8 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $214M | 8 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $161M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $173M | 6 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $201M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $251M | 8 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.